HomeMOLN • SWX
add
Molecular Partners AG
Nakaraang pagsara
CHF 3.36
Sakop ng araw
CHF 3.37 - CHF 3.40
Sakop ng taon
CHF 2.70 - CHF 5.10
Market cap
136.87M CHF
Average na Volume
48.82K
P/E ratio
-
Dividend yield
-
Primary exchange
SWX
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (CHF) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 3.60M | -18.25% |
Net na kita | -11.84M | 27.85% |
Net profit margin | — | — |
Kita sa bawat share | -0.33 | 32.65% |
EBITDA | -11.40M | 18.54% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (CHF) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 104.52M | -27.22% |
Kabuuang asset | 112.15M | -27.27% |
Kabuuang sagutin | 16.62M | 7.70% |
Kabuuang equity | 95.53M | — |
Natitirang share | 37.40M | — |
Presyo para makapag-book | 1.32 | — |
Return on assets | -25.23% | — |
Return on capital | -29.02% | — |
Cash Flow
Net change in cash
| (CHF) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -11.84M | 27.85% |
Cash mula sa mga operasyon | -9.93M | 25.27% |
Cash mula sa pag-invest | 10.66M | -25.01% |
Cash mula sa financing | -304.00K | -1.00% |
Net change in cash | 384.00K | 481.82% |
Malayang cash flow | -5.40M | 33.24% |
Tungkol
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Itinatag
2004
Website
Mga Empleyado
153
